ACOG
HEALTHCAREAlpha Cognition Inc
Live · NASDAQ · May 9, Close
What's Moving ACOG Today?
No stock-specific AI insight has been generated for ACOG yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.38
Fundamentals
Trading
ACOG News
20 articles- Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseYahoo Finance·May 7, 2026
- Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026Yahoo Finance·Apr 28, 2026
- Alpha Cognition Inc. to Participate in Three Upcoming Investor ConferencesYahoo Finance·Apr 27, 2026
- Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany SensenigYahoo Finance·Apr 20, 2026
- Alpha Cognition Inc.'s (NASDAQ:ACOG) Path To ProfitabilityYahoo Finance·Apr 19, 2026
- Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 16, 2026
- Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?Yahoo Finance·Apr 2, 2026
- Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain InjuryYahoo Finance·Apr 1, 2026
- Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425Yahoo Finance·Apr 1, 2026
- Alpha Cognition (ACOG) Q4 2025 Earnings TranscriptMotley Fool·Apr 1, 2026
- Alpha Cognition Inc. Common Stock Q4 2025 Earnings Call SummaryMoby·Mar 27, 2026
- Alpha Cognition Q4 Earnings Call HighlightsMarketbeat·Mar 26, 2026
- Alpha Cognition Inc. (ACOG) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 26, 2026
- Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational UpdateYahoo Finance·Mar 26, 2026
- Water Giant With $7 Billion in Revenue Draws $7.5 Million Investment, and Shares Are Surging This YearMotley Fool·Mar 15, 2026
- Payments Stock Down 30% Draws $6 Million Bet as Company Posts $4 Billion in RevenueMotley Fool·Mar 15, 2026
- Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026Yahoo Finance·Mar 13, 2026
- Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer’s Association International ConferencesYahoo Finance·Mar 10, 2026
- Solas Capital Loads Up On Kyndryl With 407,000 Shares BoughtMotley Fool·Mar 5, 2026
- Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness StudyYahoo Finance·Feb 25, 2026
All 20 articles loaded
Price Data
52-Week Range
$6.38
Fundamentals
Trading
About Alpha Cognition Inc
Alpha Cognition Inc. is an innovative biopharmaceutical firm focused on developing advanced therapies for neurodegenerative diseases, particularly Alzheimer's disease. Its flagship product, ACOG-100, aims to improve cognitive function and fulfill critical unmet medical needs among the aging population. Leveraging a proprietary neuroscience platform and a comprehensive R&D strategy, the company is poised to make significant strides in patient care. As Alpha Cognition progresses with its clinical pipeline and explores new therapeutic options, it presents an appealing investment opportunity for institutional investors seeking to engage with the transformative healthcare sector.